CAR T-Cell Therapy

CAR T-cell therapy uses your own modified T cells to recognise selected cancer cells and support treatment of some blood cancers.

CAR T-cell therapy is a form of cellular immunotherapy. T cells are collected from your blood, modified in a specialist laboratory so they can recognise a target on cancer cells, multiplied, and returned to you by infusion. The modified cells can then seek and attack cells carrying that target.

This is a complex treatment delivered through a specialist team. Eligibility depends on the cancer type, its target, previous treatment, current health and the availability of an appropriate product.

First, your team confirms the diagnosis and checks whether the cancer carries the target required for the therapy. Blood is collected through a line or needle, and your cells are sent for manufacture. You may receive treatment to control the cancer while the cells are prepared.

After the cells return, a short course of conditioning chemotherapy creates space for the modified cells. The CAR T cells are then infused, followed by close observation in hospital or a specialist setting. Tell the team about every medicine and symptom during this period.

Fever, chills, low blood pressure, fast heartbeat, tiredness and nausea can occur when the immune system becomes strongly activated. This reaction is called cytokine release syndrome and can range from mild to life-threatening. It needs immediate assessment by the treatment team.

Neurological effects can include headache, confusion, difficulty speaking, unusual sleepiness, tremor or seizures. Low blood counts can increase the risk of infection, bleeding and anaemia. Report symptoms promptly; do not wait for the next appointment. Your team may use medicines and intensive monitoring when needed.

The response to CAR T-cell therapy varies with the cancer, target, disease burden, previous treatment and general health. Some people have a meaningful response, while others may need additional treatment or may not respond. Your team will explain the aim of treatment and how response will be assessed.

Follow-up checks look at symptoms, blood tests and imaging or other disease assessments when appropriate. Because delayed effects can occur, keep the treatment alert information with you and follow the team’s instructions about urgent contact.

CAR T-cell therapy is made for an individual from collected immune cells. It is not the same as a routine infusion of donor blood or a standard chemotherapy course. The treatment pathway includes cell collection, manufacturing, conditioning, infusion and monitored recovery.

CAR T-cell therapy is considered for selected blood cancers when the cancer has the required target and other eligibility conditions are met. It may be discussed for some forms of [Acute Lymphoblastic Leukaemia](/conditions/acute-lymphoblastic-leukaemia/), [Diffuse Large B-Cell Lymphoma](/conditions/diffuse-large-b-cell-lymphoma/), [Lymphoma](/conditions/lymphoma/) or [Multiple Myeloma](/conditions/multiple-myeloma/). The exact indication depends on the approved treatment and specialist assessment.

Your centre will give an individual schedule. The usual pathway has several linked stages.

The first period after infusion requires especially close observation because immune and neurological reactions can develop quickly. Low blood counts and infection vulnerability may persist after discharge. Fatigue and reduced concentration can affect daily activities, and your centre may set rules about driving, travel and staying near urgent care. Keep all follow-up appointments and contact instructions.

Serious risks include cytokine release syndrome, neurological toxicity, infection, low blood counts and reactions related to treatment. The risk profile differs between products and patients. Seek urgent help for fever, breathing difficulty, faintness, confusion, a seizure, severe drowsiness or new trouble speaking, using the emergency instructions supplied by your centre.

Alternatives depend on the cancer and previous treatment. They may include chemotherapy, antibody-based treatment, targeted medicines, radiotherapy, another cellular approach or a transplant. An [Allogeneic Stem Cell Transplant](/treatments/cellular-and-transplant-therapy/allogeneic-stem-cell-transplant/) uses blood-forming cells from a donor and has a different preparation, recovery and risk profile.

Ask whether the centre has a dedicated cellular therapy team, inpatient monitoring, emergency access and coordinated follow-up. Discuss who will care for you after discharge, how far you should remain from the centre, which caregiver support is needed, and what symptoms require immediate contact.